



**Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #10-23) 3/01/2023 Clarus Therapeutics
Inc (CRXTQ, CRXWQ)**

Notice has been received that the above Company's First Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation became effective on 02/28/2022. Pursuant to the plan, all Interests shall be cancelled and extinguished as of the Effective Date, and owners thereof shall receive no Distribution on account of such Interests. See the Company's First Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation for more details.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Market Operations- 1-866-7760800.

¹ See *e.g., In re: Clarus Therapeutics Holdings, Inc., et al.*, Case No. 22-10845 (MFW) (Jointly Administered) First Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation of Clarus Therapeutics Holdings, Inc. and Clarus Therapeutics, Inc.